Physician profile
Robert M Margolis
NPI 1912925215
$652.11
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $652.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $246.87 | 2019 | |
| Glaxosmithkline, LLC. | $178.00 | 2019 | |
| Jazz Pharmaceuticals INC. | $63.85 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.92 | 2019 | |
| Sunovion Pharmaceuticals INC. | $35.24 | 2019 | |
| Shire North American Group INC | $28.85 | 2019 | |
| Grifols USA, LLC | $23.95 | 2019 | |
| Mylan Specialty L.P. | $19.63 | 2019 | |
| Genzyme Corporation | $17.80 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Margolis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.